logo-loader
viewInMed Pharmaceuticals, Inc.

InMed CEO says 'tremendous potential' for its cannabinoid-based therapy to treat glaucoma

InMed Pharmaceuticals Inc (CSE:IN) (OTCMKTS:IMLFF) CEO Eric Adams sat down with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco. Based in Vancouver, British Columbia, the pre-clinical stage biopharmaceutical company specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.

Quick facts: InMed Pharmaceuticals, Inc.

Price: 0.375 CAD

TSX:IN
Market: TSX
Market Cap: $64.61 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Algernon Pharmaceuticals receives US FDA clearance for Phase 2b/3 human study

Algernon Pharmaceuticals Inc. (CSE: AGN-OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive Vancouver with major news for the company that they have received clearance from the U.S. FDA for its multinational Phase 2b/3 study of Ifenprodil as a potential treatment for...

1 hour, 28 minutes ago

2 min read